Simplex Trading
AUTL

Simplex Trading’s Autolus Therapeutics AUTL Stock Holding History

Simplex Trading’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,641
Closed -$37.1K – 9261
2026
Q1 		$32.6K Sell
23,641
-34,278
-59% -$52.1K ﹤0.01% 6302
2025
Q4 		$115K Buy
57,919
+44,366
+327% +$68.2K ﹤0.01% 4855
2025
Q3 		$22K Buy
13,553
+11,041
+440% +$21.6K ﹤0.01% 7236
2025
Q2 		$5K Buy
+2,512
New +$4.15K ﹤0.01% 7705
2025
Q1 		– Sell
-18,057
Closed -$36.7K – 8490
2024
Q4 		$42K Buy
18,057
+9,241
+105% +$31.2K ﹤0.01% 6040
2024
Q3 		$32K Buy
8,816
+8,800
+55,000% +$35.1K ﹤0.01% 6290
2024
Q2 		$0 Sell
16
-7,401
-100% -$31.9K ﹤0.01% 8742
2024
Q1 		$47K Sell
7,417
-6,274
-46% -$39.1K ﹤0.01% 6307
2023
Q4 		$88K Sell
13,691
-4,336
-24% -$16.5K ﹤0.01% 5510
2023
Q3 		$42K Buy
+18,027
New +$51.4K ﹤0.01% 5956

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Simplex Trading's AUTL Position: Q2 2026 in Review

Simplex Trading sold out of Autolus Therapeutics (AUTL) in Q2 2026, closing a stake of 23,641 shares — an estimated $37.1K sold.

Simplex Trading first reported a position in AUTL in Q3 2023 and held it in 10 quarters. The position peaked at $115K in Q4 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Simplex Trading reported no remaining Autolus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Simplex Trading sold 23,641 Autolus Therapeutics shares in Q2 2026, an estimated $37.1K.
  • Simplex Trading first reported a position in Autolus Therapeutics in Q3 2023 and held it in 10 quarters.
  • Simplex Trading's Autolus Therapeutics position peaked at $115K in Q4 2025.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.